EBOO therapy in Melbourne, screened by a physician and administered by a registered nurse. EBOO draws blood from the body, exposes it to a controlled oxygen-ozone mixture, and returns it through a closed-loop system. Learn how it works, the evidence behind each claimed benefit, and the safety considerations before you book.
EBOO therapy is now offered in Melbourne as a physician-supervised procedure. Standard EBOO uses a specialised extracorporeal apparatus that processes several litres of heparinised blood per session, exposing it to a controlled oxygen-ozone mixture before returning it to the body. Dosimetry research found this dialysis-style approach can deliver substantially more total ozone per session than simpler ozone administration. That reflects delivery volume, not proven clinical benefit.
Blood is drawn, treated and returned through one sealed circuit.
Ozone is metered by clinical equipment, never administered at home.
Enhanced protocols add filtration and photobiomodulation.
From draw to return, administered by a registered nurse.
Clinical trial, proposed mechanism or marketing description: each claim carries a very different level of confidence.
The one area with EBOO-specific controlled-trial data. In 28 peripheral artery disease patients, EBOO was associated with greater regression of skin lesions than IV prostacyclin, plus less pain and itching. It should not be generalised to healthy adults.
Ask a physician →
Rests on mechanistic research: controlled oxidative exposure is thought to modulate immune and endothelial cell activity. No EBOO trial has measured inflammatory or immune biomarkers as a primary outcome.
Ask a physician →
The claim with the least direct evidence. Commonly described in wellness marketing, but not confirmed in controlled human trials. Treat it as plausible rather than clinically demonstrated.
Ask a physician →
Below a threshold ozone has no effect; a moderate therapeutic window is linked to adaptive antioxidant responses; higher doses risk overwhelming antioxidant capacity. This is why dosing stays in clinical hands.
Ask a physician →
Extracorporeal systems process a larger blood volume and deliver more total ozone per session. This reflects delivery capacity, not proven superior outcomes.
Ask a physician →EBOO and therapeutic plasma exchange are distinct procedures with different mechanisms and evidence bases. Your physician can explain which, if either, suits your situation.
Ask a physician →
The EBOO-specific evidence base is thin, older, and produced almost entirely by a single Italian research group. It is critical to separate it from the larger, more rigorous body of research on medical ozone therapy in general.
Greater regression of skin lesions than IV prostacyclin in peripheral artery disease.
Uncontrolled, from the same group. Nothing beyond it at comparable scale.
Robust evidence for four ozone indications only. EBOO was not among them.
EBOO and ozone-based therapies are not FDA-approved treatments for any disease.
A qualified physician reviews your history and screens for contraindications such as G6PD deficiency.
An RN draws heparinised blood into a sealed, closed-loop circuit.
Blood is exposed to a controlled oxygen-ozone mixture, then filtered and treated with photobiomodulation.
Blood returns to the body through the same circuit. The full session takes about 90 minutes.
The EBOO-specific safety signal is reassuring but limited. Individual risk assessment by a qualified physician is a necessary step before any session, not an optional formality.
Covering the draw, oxygenation and ozonation, filtration, light therapy and return.
There is no large-trial-backed protocol for how often to have sessions.
Frequency varies by individual and is set with your supervising physician.
Given the limited evidence, no specific result or timeline should be promised.
EBOO therapy is available at our Melbourne clinic after a physician screening. Request a consultation and we will confirm the location, your screening appointment and the next available session time.
EBOO (Extracorporeal Blood Oxygenation and Ozonation) draws blood, exposes it to a controlled oxygen-ozone mixture, and returns it to the body. Researchers have proposed potential relevance to peripheral arterial disease, coronary disease, cholesterol embolism, and severe dyslipidaemia, though these remain proposed rather than confirmed applications.
Claimed benefits include improved circulation, reduced inflammation, immune support, and increased energy. The strongest evidence supports improved vascular skin lesions in a small peripheral artery disease trial; other claimed benefits rest mainly on proposed mechanisms rather than dedicated trials.
The available EBOO-specific data reported no serious adverse effects or treatment complications, but these are small samples, not a large safety database. Rare, serious complications have been reported with other ozone-administration routes, which is why physician oversight and screening matter.
Documented risks include rare cases of encephalopathy and haemolytic anaemia with deep vein thrombosis, though these were linked to unsupervised, non-extracorporeal routes rather than EBOO specifically. G6PD deficiency and similar conditions are a standard screening consideration.
EBOO is the general extracorporeal technique. EBO2 is an enhanced, physician-supervised implementation that adds a filtration step and photobiomodulation within a closed-loop, RN-administered system.
EBOO and plasmapheresis (therapeutic plasma exchange) are distinct procedures with different mechanisms and evidence bases.
EBOO-specific evidence is limited to one small controlled trial and one uncontrolled case series from the same research group, with encouraging but narrow results in peripheral artery disease patients. Broader ozone-therapy research shows a favourable but low-certainty safety profile in unrelated conditions, but that evidence excludes EBOO trials.
People with conditions that impair tolerance to oxidative stress, such as G6PD deficiency, are a standard screening consideration. A qualified physician should evaluate individual risk factors and contraindications before any session.
A typical session takes approximately 90 minutes, covering the draw, oxygenation and ozonation, filtration, photobiomodulation, and return. There is no standardised protocol for session frequency; this varies by clinic and individual.
Online consultation requests are currently unavailable.
Claimed benefits are supported mainly by mechanism-level research and one small controlled trial.
The strongest data involves peripheral artery disease skin lesions, not general wellness.
Broader ozone research is favourable but excludes EBOO trials and covers different conditions.
EBOO and ozone-based therapies are not FDA-approved treatments for any disease.
Serious complications are rare and mostly linked to unsupervised or non-EBOO routes.
Screening for contraindications comes before any session.